Zentiva Group Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
4,800
- Stock Symbol
-
1SKF401E
- Investments
-
11
- Share Price
-
$34.43
- (As of Thursday Closing)
Zentiva Group General Information
Description
Zentiva AS is engaged in the development, production, and distribution of generic medicines. It operates in more than 25 European markets. The company therapeutic areas inlcude Cardiovascular, Central nervous system, Gastrointestinal and metabolic disorders, Anti-inflammatory and pain, Ophthalmology, Anti-infectives, Urology, Respiratory, Blood disorders, and Oncology.
Contact Information
Website
www.zentiva.comCorporate Office
- U Kabelovny 529/16
- Dolní Měcholupy
- Prague, 102 00
- Czech Republic
Corporate Office
- U Kabelovny 529/16
- Dolní Měcholupy
- Prague, 102 00
- Czech Republic
Zentiva Group Timeline
Zentiva Group Stock Performance
As of 19-Jun-2025, Zentiva Group’s stock price is $34.43.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $34.43 | $34.65 | $25.03 - $35.94 | 4.14 |
Zentiva Group Financials Summary
As of 31-Dec-2015, Zentiva Group has a trailing 12-month revenue of $126M.
|
In Thousands, USD |
TTM 31-Dec-2015 | FY 2015 31-Dec-2015 | FY 2014 31-Dec-2014 |
|---|---|---|---|
| Revenue | 125,622 | 125,622 | 185,331 |
| EBITDA | 37,918 | 37,918 | 67,796 |
| Net Income | 19,452 | 19,452 | 53,052 |
| Total Assets | 149,351 | 149,351 | 191,232 |
| Total Debt | 0 | 0 | 23 |
Zentiva Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Zentiva Group Comparisons
Industry
Financing
Details
Zentiva Group Competitors (84)
One of Zentiva Group’s 84 competitors is Anavex Life Sciences, a Corporation company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Anavex Life Sciences | Corporation | New York, NY | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Gilead Sciences | Formerly VC-backed | Foster City, CA | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA |
Zentiva Group Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Zentiva Group Patents
Zentiva Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202418754-D0 | Method for producing (s)-amlodipine succinate | Pending | 19-Dec-2024 | ||
| GB-202407194-D0 | Pending | 21-May-2024 | |||
| EP-4552633-A1 | Pharmaceutical compositions comprising amorphous solid solutions of rivaroxaban and copovidone and preparation methods thereof | Pending | 10-Nov-2023 | ||
| GB-202317232-D0 | Pharmaceutical compositions comprising amorphous solid solutions of rivaroxaban and copovidone and preparation methods thereof | Inactive | 10-Nov-2023 | ||
| EP-4505998-A1 | Pharmaceutical composition containing dapagliflozin and metformin | Pending | 08-Aug-2023 | A61K31/155 |
Zentiva Group Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Zentiva Group Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Zentiva Group Investments & Acquisitions (11)
Zentiva Group’s most recent deal was a Buyout/LBO with Aboca (Five Heritage Brand). The deal was made on 16-Jun-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aboca (Five Heritage Brand) | 16-Jun-2025 | Buyout/LBO | Pharmaceuticals | ||
| Apontis Pharma | 13-Jun-2025 | Secondary Transaction - Private | Pharmaceuticals | ||
| Apontis Pharma | 09-Dec-2024 | Buyout/LBO | Pharmaceuticals | ||
| Blokurima | 01-Nov-2024 | Buyout/LBO | Pharmaceuticals | ||
| Sanofi (Zerinol and Schoum Solution) | 06-Dec-2022 | Buyout/LBO | Pharmaceuticals |
Zentiva Group Exits (1)
Zentiva Group’s most recent exit was on 11-Aug-2003 from Saneca Pharmaceuticals. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Saneca Pharmaceuticals | 11-Aug-2003 | Completed |
|
Zentiva Group Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Apontis Pharma | Monheim am Rhein, Germany | 1946 | |
| Blokurima | Prague, Czech Republic |
Zentiva Group FAQs
-
When was Zentiva Group founded?
Zentiva Group was founded in 1993.
-
Where is Zentiva Group headquartered?
Zentiva Group is headquartered in Prague, Czech Republic.
-
What is the size of Zentiva Group?
Zentiva Group has 4,800 total employees.
-
What industry is Zentiva Group in?
Zentiva Group’s primary industry is Drug Discovery.
-
Is Zentiva Group a private or public company?
Zentiva Group is a Public company.
-
What is Zentiva Group’s stock symbol?
The ticker symbol for Zentiva Group is 1SKF401E.
-
What is the current stock price of Zentiva Group?
As of 19-Jun-2025 the stock price of Zentiva Group is $34.43.
-
What is Zentiva Group’s current revenue?
The trailing twelve month revenue for Zentiva Group is $126M.
-
Who are Zentiva Group’s competitors?
Anavex Life Sciences, Astellas Pharma, Merck & Co., Gilead Sciences, and Dicerna Pharmaceuticals are some of the 84 competitors of Zentiva Group.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
